According to Zhitong Finance App, Kang Fang Biotech (09926.HK) announced that the new drug marketing application (SNDA) for first-line treatment of advanced squamous non-small cell lung cancer (SqnsCLC) with the world's first bispecific antibody (PD-1/VEGF) developed by the company has been approved for listing by the China National Drug Administration (NMPA). This is the third indication that Evosi has been approved for marketing.

Zhitongcaijing · 1d ago
According to Zhitong Finance App, Kang Fang Biotech (09926.HK) announced that the new drug marketing application (SNDA) for first-line treatment of advanced squamous non-small cell lung cancer (SqnsCLC) with the world's first bispecific antibody (PD-1/VEGF) developed by the company has been approved for listing by the China National Drug Administration (NMPA). This is the third indication that Evosi has been approved for marketing.